114358-14-4

Basic information

• Product Name: O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate
• Synonyms: O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate
• CAS NO: 114358-14-4
• Molecular Weight: 393.555
• Mol File: 114358-14-4.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate(114358-14-4)
• EPA Substance Registry System: O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate(114358-14-4)

Safety Data

• Hazardous Substances Data: 114358-14-4(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 288-32-4 1H-imidazole 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 51-35-4 4R-4-hydroxyproline 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 

Relevant articles and documents

Solvent-free organocatalytic asymmetric conjugate addition of thiols to α,β-unsaturated aldehydes

A highly enantioselective asymmetric conjugate addition of thiols to α,β-unsaturated aldehydes has been achieved catalyzed by newly designed organocatalyst without solvent. Copyright

CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS

Conformationally constrained macrocyclic compounds of formula (I), including substituents E with at least one ester moiety, G and Q, as defined in the description and the claims, and salts thereof, can be metabolized to compounds that have the property to

Process Development and Synthesis of Birinapant: Large Scale Preparation and Acid-Mediated Dimerization of the Key Indole Intermediate

Birinapant/TL32711 (1) is a novel bivalent antagonist of the inhibitor of apoptosis (IAP) family of proteins which is currently in clinical development for the treatment of cancer and hepatitis B virus (HBV) infection. In this report, we present a detaile